Board of Directors

The CMPI Board of Directors is comprised of some of the nation’s leaders in academic medical research, clinical practice, health care delivery, patient advocacy, innovation leadership and science reporting. The board will be involved in helping CMPI reaching a broader group of stakeholders in their respective communities and in shaping CMPI programs in the future.

Peter J. Pitts
President,
Center for Medicine in the Public Interest

Robert M. Goldberg
Vice President & Director of Programs,
Center for Medicine in the Public Interest

Steven Sammut
Lecturer,
Wharton School, the Law School and the School of Engineering and Applied Science of the University of Pennsylvania

Mark Thornton, M.D., Ph.D.
Chairman and President,
Sarcoma Foundation of America

Michael Weber, M.D.
Professor of Medicine,
SUNY Downstate College of Medicine
Brooklyn, New York
Sign Up for Our Email Newsletter

RECENT NEWS

Waiving COVID-19 Vaccine Patents: A Bad Idea and a Dangerous Precedent

Waiving COVID-19 Vaccine Patents: A Bad Idea and a Dangerous Precedent

Waiving patent protection discourages cutting-edge research investments, which in turn produce breakthrough treatments no...  Read more

'I'm hopeful for the future': Alzheimer's drug approved by FDA

'I'm hopeful for the future': Alzheimer's drug approved by FDA

Peter Pitts of CMPI and Dr. Ronald Petersen of the Mayo Clinic discuss the FDA's approval of aducanumab...  Read more

Biosimilar Strength vs. Potency: Avoiding a Regulatory Hobson’s Choice

Biosimilar Strength vs. Potency: Avoiding a Regulatory Hobson’s Choice

Biosimilars bring lower costs and greater access to the market for biological products, but FDA must determine a predicta...  Read more

DRUGWONKS BLOG